2019
PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES
Carniti C, Biancon G, Banfi S, Vella C, Magni M, Pennisi M, Anna D, Guidetti A, Corradini P. PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES. HemaSphere 2019, 3: 599-600. DOI: 10.1097/01.hs9.0000563532.69483.ec.Peer-Reviewed Original ResearchCell-free DNADLBCL patientsIgH gene rearrangementTumor burdenResidual diseaseIgH rearrangementsGene rearrangementsDiffuse large B-cell lymphoma patientsLarge B-cell lymphoma patientsB-cell lymphoma patientsDiffuse large B-cell lymphomaLarge B-cell lymphomaPossible disease progressionPossible residual diseaseR-CHOP therapyBaseline plasma samplesLymph node biopsyDisease monitoringImmunoglobulin heavy chain gene rearrangementMultiple myeloma patientsNon-invasive disease monitoringCell lymphoma patientsNumber of patientsFFPE samplesPET-CT scan
2016
Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene Rearrangements
Gimondi S, Biancon G, Vendramin A, Zaninelli S, Rizzitano S, Malan S, Bermema A, Montefusco V, Carniti C, Corradini P. Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene Rearrangements. Blood 2016, 128: 4430. DOI: 10.1182/blood.v128.22.4430.4430.Peer-Reviewed Original ResearchCell-free tumor DNAMinimal residual diseaseIgH gene rearrangementMultiple myeloma patientsTime pointsTumor burdenMyeloma patientsGene rearrangementsLiquid biopsyPlasma samplesInternational Myeloma Working Group Uniform Response CriteriaTime of CRSequential plasma samplesBone marrow infiltrationDisease monitoringResidual tumor burdenNon-invasive strategyImmunoglobulin gene rearrangementsMM ptsPresence of subclonesSpecific clonotypesProgressive diseaseMarrow infiltrationMRD monitoringResidual disease